Arca Biopharma | ABIO - Selling And Administration Expenses


Arca Biopharma reported $5.16M in Selling and Administration Expenses for its fiscal quarter ending in March of 2025.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
Amgen USD 1.94B 237M Dec/2025
Arca Biopharma USD 5.16M 346K Mar/2025
Biogen USD 545.2M 38.6M Sep/2025
Brainstorm Cell Therapeutics USD 1.78M 319K Mar/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Capricor Therapeutics USD 5.88M 1.6M Mar/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Laboratory Of America USD 538.6M 13.8M Dec/2025
Myriad Genetics USD 129M 1.3M Sep/2025
Otsuka Holdings JPY 278.3B 24.08B Dec/2025
Pfizer USD 4.08B 894M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025